The "trumpflation" Trade Could Get Worse Before…

Medtronic is turning things around

Medtronic is one of the world’s largest medical device makers. The stock has a historically high 3.3% yield backed by a dividend that has been increased for 49 consecutive years, which is just one year shy of Dividend King status. The stock’s price-to-sales and price-to-earnings ratios are both below their five-year averages. It should interest both dividend investors and value investors.

But why is Medtronic so cheap? The answer is that, over time, the medical device maker’s business got bloated, and growth slowed. That’s not uncommon, and management got to work on a fix, refocusing on its highest growth and most profitable businesses and exiting less desirable divisions. The heavy lifting has been done, and it looks Medtronic has turned a corner.

Expand

NYSE: MDT

Medtronic

Premium Feature

Moneyball Superscore

75/100

Today’s Change

(-1.00%) $-0.88

Current Price

$87.09

Key Data Points

Market Cap

$111BMarket cap calculated using publicly traded s outstanding only. Does not include unlisted, private, or dual-class non-traded s. Implied market cap may vary.

Day’s Range

$86.44 – $88.50

52wk Range

$73.31 – $106.33

Volume

52.1M

Avg Vol

10.7M

Gross Margin

60.56%

Dividend Yield

3.28%

Wall Street still doesn’t give the company any credit, but you may want to jump in while the stock still appears to be on sale. Notably, fiscal 2026 saw the highest sales growth in a decade at 8.4%. But the first quarter of fiscal 2027 was even better, coming in with sales growth of nearly 14%. New products, including the Hugo surgical robot, are helping drive the top line. If inflation has you worried, this out-of-favor healthcare stock could be a great pick if you have a value and/or income focus.

Eli Lilly is tapped into a massive growth market

Eli Lilly is at the other extreme on the valuation front. While its P/S and P/E ratios are below their five-year averages, they are both high on an absolute basis. The stock’s 0.6% dividend yield is even lower than the miserly 1% you’d get from the S&P 500 index (^GSPC +0.58%). However, Eli Lilly is the leader in the GLP-1 weight-loss space. Growth investors may want to dig in.

GLP-1 drugs are relatively new, and demand has been huge. At this point, the company’s weight-loss drugs account for roughly two-thirds of its sales. That’s a risk, noting that drugs have time-limited patent protection. But the weight-loss market is ly to continue expanding as pills become the dominant delivery method. So the GLP-1 story probably hasn’t fully played out yet.

Expand

NYSE: LLY

Eli Lilly

Premium Feature

Moneyball Superscore

94/100

Today’s Change

(1.26%) $14.37

Current Price

$1,157.49

Key Data Points

Market Cap

$1.1TMarket cap calculated using publicly traded s outstanding only. Does not include unlisted, private, or dual-class non-traded s. Implied market cap may vary.

Day’s Range

$1139.98 – $1177.07

52wk Range

$783.85 – $1292.65

Volume

2.1M

Avg Vol

2.5M

Gross Margin

83.40%

Dividend Yield

0.58%

That said, the long-term appeal here is that Eli Lilly is using the cash it is generating from its weight-loss drugs to broaden its drug pipeline. Acquisitions have expanded the pharmaceutical giant into new treatment spaces, positioning it well for post-GLP-1 growth. This is a company that’s hitting on all cylinders right now and using that success as the engine block for the future. Inflation is unly to slow Eli Lilly down.

Consumers will pay to be healthy

Inflation is a problem, and it will impact many industries. Historically, healthcare has been resilient to inflation because medical care isn’t really a discretionary item. For investors with a value or income bias, Medtronic is probably worth considering while Wall Street continues to ignore the increasingly obvious success of its turnaround. Eli Lilly is a growth-oriented story, but one that increasingly includes opportunities beyond GLP-1 weight-loss drugs.

Read Next

Oct 4, 2026 •By Reuben Gregg Brewer

2 High-Yield Stocks to Buy in October Without Any Hesitation

Oct 2, 2026 •By Matt DiLallo

Dividend Kings of 2026

Oct 1, 2026 •By Reuben Gregg Brewer

Kevin Warsh’s Inflation Stance Makes These Cheap Dividend Stocks Look a Lot More Attractive

Oct 1, 2026 •By Matt DiLallo

History Says Johnson & Johnson Beats Medtronic. Here’s Why I’d Still Consider MDT for the Next Decade.

Sep 29, 2026 •By David Jagielski, CPA

3 Absurdly Cheap Growth Stocks That Are Trading Below $100

Sep 27, 2026 •By James Halley

Medtronic’s High Dividend Yield Gets Little Attention on Wall Street — Should You Buy the Stock Anyway?

About the Author

Reuben Gregg Brewer is a contributing Motley Fool stock market analyst covering energy, utilities, REITs, and consumer staples. He is the former director of research at Value Line Publishing, where he rose from mutual fund analyst to equity analyst before leading all research operations. Reuben holds a bachelor’s degree in psychology from SUNY Purchase, a master’s in social work from Columbia University, and an MBA from Regis University. He has been featured as a financial expert on CNBC and in the Financial Times, Barron’s, and InvestmentNews.

TMFReubenGBrewer

Stocks Mentioned

Motley Fool Stock Advisor’s Latest Pick

Get Access

—% Avg Return

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.